Subependymal giant cell astrocytoma screening: Difference between revisions
Created page with "__NOTOC__ {{Subependymal giant cell astrocytoma}} {{CMG}}{{AE}}{{SR}} ==Reference== {{reflist|2}} Category:Disease Category:Types of cancer Category:Rare disease..." |
No edit summary |
||
| (9 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Subependymal giant cell astrocytoma}} | {{Subependymal giant cell astrocytoma}} | ||
{{CMG}} {{AE}}{{SR}}, {{IO}} | |||
==Overview== | |||
According to the International Tuberous Sclerosis Complex Consensus, screening for subependymal giant cell astrocytoma by [[MRI]] is recommended every 1-3 years among patients with [[tuberous sclerosis]], even in the abscence of [[symptoms]]. | |||
== | ==Screening== | ||
According to the International Tuberous Sclerosis Complex Consensus, screening for subependymal giant cell astrocytoma by [[MRI]] is recommended every 1-3 years among patients with [[tuberous sclerosis]], even in the abscence of [[symptoms]].<ref name="RothRoach2013">{{cite journal|last1=Roth|first1=Jonathan|last2=Roach|first2=E. Steve|last3=Bartels|first3=Ute|last4=Jóźwiak|first4=Sergiusz|last5=Koenig|first5=Mary Kay|last6=Weiner|first6=Howard L.|last7=Franz|first7=David N.|last8=Wang|first8=Henry Z.|title=Subependymal Giant Cell Astrocytoma: Diagnosis, Screening, and Treatment. Recommendations From the International Tuberous Sclerosis Complex Consensus Conference 2012|journal=Pediatric Neurology|volume=49|issue=6|year=2013|pages=439–444|issn=08878994|doi=10.1016/j.pediatrneurol.2013.08.017}}</ref><ref name="pmid21465222">{{cite journal| author=Campen CJ, Porter BE| title=Subependymal Giant Cell Astrocytoma (SEGA) Treatment Update. | journal=Curr Treat Options Neurol | year= 2011 | volume= 13 | issue= 4 | pages= 380-5 | pmid=21465222 | doi=10.1007/s11940-011-0123-z | pmc=PMC3130084 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21465222 }} </ref> | |||
==References== | |||
{{reflist|2}} | {{reflist|2}} | ||
| Line 15: | Line 19: | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Neurology]] | |||
[[Category:Neurosurgery]] | |||
Latest revision as of 19:53, 5 November 2019
|
Subependymal giant cell astrocytoma Microchapters |
|
Differentiating Subependymal Giant Cell Astrocytoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Subependymal giant cell astrocytoma screening On the Web |
|
American Roentgen Ray Society Images of Subependymal giant cell astrocytoma screening |
|
Risk calculators and risk factors for Subependymal giant cell astrocytoma screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2], Ifeoma Odukwe, M.D. [3]
Overview
According to the International Tuberous Sclerosis Complex Consensus, screening for subependymal giant cell astrocytoma by MRI is recommended every 1-3 years among patients with tuberous sclerosis, even in the abscence of symptoms.
Screening
According to the International Tuberous Sclerosis Complex Consensus, screening for subependymal giant cell astrocytoma by MRI is recommended every 1-3 years among patients with tuberous sclerosis, even in the abscence of symptoms.[1][2]
References
- ↑ Roth, Jonathan; Roach, E. Steve; Bartels, Ute; Jóźwiak, Sergiusz; Koenig, Mary Kay; Weiner, Howard L.; Franz, David N.; Wang, Henry Z. (2013). "Subependymal Giant Cell Astrocytoma: Diagnosis, Screening, and Treatment. Recommendations From the International Tuberous Sclerosis Complex Consensus Conference 2012". Pediatric Neurology. 49 (6): 439–444. doi:10.1016/j.pediatrneurol.2013.08.017. ISSN 0887-8994.
- ↑ Campen CJ, Porter BE (2011). "Subependymal Giant Cell Astrocytoma (SEGA) Treatment Update". Curr Treat Options Neurol. 13 (4): 380–5. doi:10.1007/s11940-011-0123-z. PMC 3130084. PMID 21465222.